Loading news...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. With little debt on their balance sheets, these companies can consider acquisitions.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list.
CORAL GABLES, Fla. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced their inaugural Catalyst Advocacy Scholars Summit (CASS).
Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals (CPRX +0.21%), exercised and immediately sold 10,983 shares of common stock on November 26, 2025, for a total value of approximately $256,200, as disclosed in this SEC Form 4 filing.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) and Organogenesis (NASDAQ: ORGO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends. Profitability This table compares Catalyst Pharmaceuticals and Organogenesis' net
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Toth Financial Advisory Corp trimmed its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 96.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,150 shares of the biopharmaceutical company's stock after selling 59,200 shares during the period.
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX - Get Free Report) Director Molly Harper sold 26,746 shares of the firm's stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total value of $621,844.50. Following the sale, the director directly owned 2,360 shares in the company, valued at
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
The mean of analysts' price targets for Catalyst (CPRX) points to a 42.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?